Log In
BCIQ
Print this Print this
 

TT-100

  Manage Alerts
Collapse Summary General Information
Company TriAct Therapeutics Inc.
DescriptionDual IGF1R/EGFR inhibitor
Molecular Target Insulin-like growth factor-1 (IGF-1) receptor (IGF1R) (CD221) ; Epidermal growth factor receptor (EGFR)
Mechanism of ActionEpidermal growth factor (EGF) receptor kinase inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationNon-small cell lung cancer (NSCLC)
Indication DetailsTreat non-small cell lung cancer (NSCLC)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today